Implementation of HER2 Testing in Endometrial Cancer, a Summary of Real-World Initial Experience in a Large Tertiary Cancer Center

Anna Plotkin,Ekaterina Olkhov-Mitsel,Weei-Yuarn Huang,Sharon Nofech-Mozes

DOI: https://doi.org/10.3390/cancers16112100

2024-05-31

Cancers

Abstract:HER2-targeted therapies have transformed the management of advanced or recurrent serous endometrial cancer (EC), leading to an increased clinical demand for HER2 testing. Despite its adoption in select academic centers, the global extent of such tumor testing is unclear. In this study, we report on the initial two-year experience of HER2 testing at a major academic center with a reference gynecologic oncology service and biomarker reference laboratory. All patients who underwent HER2 testing based on physician discretion, reflex HER2 testing, and reference laboratory requests were included. From February 2021 to October 2023, HER2 testing was performed on 192 tumor tissue samples from 180 EC patients. Serous carcinoma constituted 52% of samples, reflecting diagnostic challenges and limited therapeutic options for advanced EC. HER2 positivity was found in 28% of all cases and 30% of p53-aberrant cases. An immunohistochemistry (IHC) score of 3+ was found in 15% of samples, while IHC 2+ was found in 45% (13% IHC 2+/ISH+ and 32% IHC 2+/ISH−). The newly identified 'HER2-low' category comprised 46% of the samples. Heterogeneity was noted in 42% of HER2-positive cases, with complex patterns in 3%. NGS and HER2 IHC-FISH showed a 24% discordance, attributed to intratumoral heterogeneity, tumor cellularity, a small number of amplified cells, and the HER2/CEP17 ratio near the cut-off. This study offers real-world insights into HER2 testing in EC, highlighting the challenges and underscoring the need for standardized guidelines in specimen handling, proficiency testing, and scoring criteria to enhance patient management and therapeutic decision-making.

oncology

What problem does this paper attempt to address?

The problems that this paper attempts to solve are the practical application situation of HER2 detection in endometrial cancer (EC) and the challenges it faces. Specifically, through this study, the researchers hope to:

1. **Evaluate the performance of HER2 detection in clinical practice**: The researchers hope to understand the implementation of HER2 detection in endometrial cancer patients in the actual clinical environment, including the frequency of detection, the positive rate, and the result consistency among different detection methods.

2. **Identify the characteristics of HER2 - positive patients**: By analyzing samples from 180 patients, the researchers hope to determine which types of endometrial cancer patients are more likely to show HER2 over - expression, thereby providing potential opportunities for targeted therapy for these patients.

3. **Explore the heterogeneity and inconsistency in HER2 detection**: The study has found that there is a certain degree of inconsistency among different detection methods (such as immunohistochemistry IHC and fluorescence in - situ hybridization FISH), especially in cases where there is heterogeneity within the tumor. The researchers hope to analyze the reasons for these inconsistencies and put forward suggestions for improving the detection methods.

4. **Propose the need for standardized guidelines**: Based on the research results, the researchers emphasize the importance of formulating standardized guidelines in aspects such as sample processing, proficiency testing, and scoring criteria, in order to improve the accuracy and reliability of HER2 detection, so as to better guide clinical decision - making and patient management.

Through the above objectives, this study aims to provide a scientific basis for precision medicine in endometrial cancer and promote the standardization and normalization of HER2 detection in clinical practice.